1,N(6)-deoxyethenoadenosine,
1,N(6)-ethenodeoxyadenosine,
1,N2-etheno-2'-deoxyguanosine,
1,N6-etheno-2'-deoxyadenosine,
2'-deoxy-2-deuteroethenoadenosine,
Ethenodeoxyadenosine,
N6-Etheno 2'-deoxyadenosine,
1,N6-Ethenodeoxyadenosine,
68498-25-9,
1,N6-Etheno-dA,
1,N6-Etheno-2'-deoxyadenosine,
N1,N6-Etheno-2'-deoxyadenosine,
BIDD:GT0712,
1,N6-etheno-2 -deoxyadenosine,
1,n6-Etheno-2-deoxy-adenosine,
SCHEMBL19666769,
XQQIMTUYVDUWKJ-DJLDLDEBSA-N,
ZINC1319891,
MFCD00056769,
CS-W010084,
ZB016280,
HY-111646,
C-44225,
3H-Imidazo[2,1-i]purine,3-(2-deoxy-b-D-erythro-pentofuranosyl)-,
(2R,3S,5R)-2-(hydroxymethyl)-5-(3H-imidazo[1,2-i]purin-3-yl)tetrahydrofuran-3-ol,
(2R,3S,5R)-2-(hydroxymethyl)-5-{3H-imidazo[2,1-f]purin-3-yl}oxolan-3-ol,
etheno-2'-deoxyadenosine,
Pomalidomide Impurity 3,
1,N(6)-Ethenodeoxyadenosine,
CCRIS 2746,
C12-H13-N5-O3,
CID10945668,
1,N6-ETHENO-2'-DEOXY-ADENOSINE,
3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3H-imidazo(2,1-i)purine,
3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3H-imidazo[2,1-i]purine,